$881.49 Million in Sales Expected for MEDNAX Inc (MD) This Quarter

Equities research analysts expect MEDNAX Inc (NYSE:MD) to report sales of $881.49 million for the current quarter, according to Zacks. Eight analysts have issued estimates for MEDNAX’s earnings, with estimates ranging from $843.18 million to $928.24 million. MEDNAX reported sales of $915.92 million during the same quarter last year, which would suggest a negative year over year growth rate of 3.8%. The company is expected to report its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that MEDNAX will report full year sales of $3.57 billion for the current fiscal year, with estimates ranging from $3.46 billion to $3.74 billion. For the next year, analysts expect that the firm will report sales of $3.73 billion, with estimates ranging from $3.63 billion to $3.92 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover MEDNAX.

MEDNAX (NYSE:MD) last announced its earnings results on Thursday, May 2nd. The company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.63 by ($0.05). The business had revenue of $851.20 million for the quarter, compared to analyst estimates of $906.35 million. MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. The firm’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.89 earnings per share.

Several brokerages have recently commented on MD. Citigroup set a $36.00 price target on shares of MEDNAX and gave the stock a “buy” rating in a research report on Friday, May 3rd. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Jefferies Financial Group reduced their price target on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a research report on Thursday, April 11th. Credit Suisse Group reduced their price target on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 13th. Finally, Mizuho set a $36.00 price target on shares of MEDNAX and gave the company a “hold” rating in a research report on Friday, February 8th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. MEDNAX has a consensus rating of “Hold” and an average price target of $40.55.

Shares of MEDNAX stock traded up $0.20 during trading hours on Friday, hitting $26.02. 627,964 shares of the company’s stock traded hands, compared to its average volume of 1,175,292. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.55 and a quick ratio of 2.55. The company has a market capitalization of $2.23 billion, a PE ratio of 7.41, a P/E/G ratio of 1.02 and a beta of 0.59. MEDNAX has a twelve month low of $25.47 and a twelve month high of $48.77.

In related news, SVP Dominic J. Andreano sold 4,608 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $30.16, for a total transaction of $138,977.28. Following the completion of the sale, the senior vice president now directly owns 64,461 shares of the company’s stock, valued at $1,944,143.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Md Pascal J. Goldschmidt sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $30.40, for a total transaction of $100,320.00. Following the sale, the director now directly owns 20,821 shares of the company’s stock, valued at $632,958.40. The disclosure for this sale can be found here. Insiders have sold 26,490 shares of company stock worth $850,766 over the last quarter. 3.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Mercantile Trust Co. boosted its holdings in MEDNAX by 13.8% during the 4th quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock worth $76,000 after acquiring an additional 275 shares during the last quarter. First Bank & Trust lifted its holdings in MEDNAX by 14.3% during the fourth quarter. First Bank & Trust now owns 2,808 shares of the company’s stock valued at $93,000 after purchasing an additional 351 shares during the last quarter. ETF Managers Group LLC lifted its holdings in MEDNAX by 18.8% during the fourth quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock valued at $79,000 after purchasing an additional 381 shares during the last quarter. Triad Investment Management lifted its holdings in MEDNAX by 0.8% during the first quarter. Triad Investment Management now owns 66,204 shares of the company’s stock valued at $1,799,000 after purchasing an additional 496 shares during the last quarter. Finally, Tompkins Financial Corp lifted its holdings in MEDNAX by 352.8% during the first quarter. Tompkins Financial Corp now owns 806 shares of the company’s stock valued at $38,000 after purchasing an additional 628 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

See Also: Why is insider trading harmful?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.